Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Pfizer
Pfizer
Merck Sharp & Dohme LLC
Pfizer
Compass Therapeutics
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Pheon Therapeutics
Eli Lilly and Company
Incyte Corporation
BigHat Biosciences, Inc.
Revolution Medicines, Inc.
Pfizer
Seagen Inc.
Turning Point Therapeutics, Inc.
Alterome Therapeutics, Inc.
GlaxoSmithKline
GlaxoSmithKline
Orano Med LLC
RasCal Therapeutics, Inc.
Elicio Therapeutics
Pfizer
RemeGen Co., Ltd.
Beijing Biotech
Xencor, Inc.
Cartography Biosciences
MedImmune LLC
Accent Therapeutics
Intima Bioscience, Inc.
Inspirna, Inc.
A2 Biotherapeutics Inc.
Mirati Therapeutics Inc.
Arvinas Inc.
MBrace Therapeutics
New Phase Ltd.
Revolution Medicines, Inc.
Vaccinogen Inc
GlaxoSmithKline
Pheon Therapeutics
GlaxoSmithKline
Shanghai Henlius Biotech
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
Novartis
Qilu Pharmaceutical Co., Ltd.
Takeda